SCHEMBL6674556

SCHEMBL6674556

O=C(O)COc1cc(OCC(=O)O)cc(C(=O)Nc2ccc(/C=C/c3ccccc3)cc2C(=O)O)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTC4S Q16873 1/20 0.45
AKR1C2 P52895 2/20 0.44
AKR1C1 Q04828 2/20 0.44
PTPN1 P18031 1/20 0.44
HNF4A P41235 1/20 0.44
MAPK1 P28482 1/20 0.44
FFAR1 O14842 1/20 0.43
PPARG P37231 1/20 0.43
PPARD Q03181 1/20 0.43
PPARA Q07869 1/20 0.43
SERPINE1 P05121 1/20 0.43
MEN1 O00255 7/20 0.43
KMT2A Q03164 7/20 0.43
GFER P55789 1/20 0.43
SNCA P37840 1/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 1/20 0.42
MAPT P10636 2/20 0.42
PKM P14618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6674560 1.00 LTC4S (0.45) LTC4SAKR1C2AKR1C1PTPN1HNF4A
SCHEMBL6674936 0.86 GCK (0.53) LTC4SPPARGPPARASERPINE1MEN1
SCHEMBL6674932 0.86 GCK (0.53) LTC4SPPARGPPARASERPINE1MEN1
SCHEMBL6677951 0.85 KDM4E (0.58) MEN1KMT2ASNCARAB9ASMN1; SMN2
SCHEMBL6677957 0.85 KDM4E (0.58) MEN1KMT2ASNCARAB9ASMN1; SMN2
SCHEMBL6678422 0.84 NR1H4 (0.51) LTC4SMEN1KMT2A
SCHEMBL6678428 0.84 NR1H4 (0.51) LTC4SMEN1KMT2A
SCHEMBL6673496 0.82 MEN1 (0.62) LTC4SAKR1C2AKR1C1PTPN1HNF4A
SCHEMBL6674346 0.82 MEN1 (0.62) LTC4SAKR1C2AKR1C1PTPN1HNF4A
SCHEMBL6675963 0.81 PTPN1 (0.56) LTC4SAKR1C2AKR1C1PTPN1HNF4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1289936-B1 SUBSTITUTED STILBENES AS GLUCOSE UPTAKE ENHANCERS TELIK INC (US) 2004-10-20 EP claimed
US-6479548-B2 P-(BENZOYLAMINO)STILBENE DERIVATIVES TELIK, INC. 2002-11-12 US claimed
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers TELIK, INC. 2002-03-14 US claimed
EP-1289936-B1 SUBSTITUTED STILBENES AS GLUCOSE UPTAKE ENHANCERS TELIK INC (US) 2004-10-20 EP disclosed
US-6479548-B2 P-(BENZOYLAMINO)STILBENE DERIVATIVES TELIK, INC. 2002-11-12 US disclosed
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers TELIK, INC. 2002-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers SLC2A1, SLC2A8, SLC2A2 LTC4S 2449/4885AKR1C2 936/4885AKR1C1 1265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.